Cargando…

Intensified antineoplastic effect by combining an HDAC-inhibitor, an mTOR-inhibitor and low dosed interferon alpha in prostate cancer cells

A significant proportion of men diagnosed with prostate cancer (PCa) eventually develop metastatic disease, which progresses to castration resistance, despite initial response to androgen deprivation. As anticancer therapy has become increasingly effective, acquired drug resistance has emerged, limi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsaur, Igor, Hudak, Lukasz, Makarević, Jasmina, Juengel, Eva, Mani, Jens, Borgmann, Hendrik, Gust, Kilian M, Schilling, David, Bartsch, Georg, Nelson, Karen, Haferkamp, Axel, Blaheta, Roman A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4549030/ https://www.ncbi.nlm.nih.gov/pubmed/25808196 http://dx.doi.org/10.1111/jcmm.12583

Ejemplares similares

Resistance after Chronic Application of the HDAC-Inhibitor Valproic Acid Is Associated with Elevated Akt Activation in Renal Cell Carcinoma In Vivo
por: Juengel, Eva, et al.
Publicado: (2013)

Cross-communication between histone H3 and H4 acetylation and Akt-mTOR signalling in prostate cancer cells
por: Makarević, Jasmina, et al.
Publicado: (2014)

HDAC Inhibition Counteracts Metastatic Re-Activation of Prostate Cancer Cells Induced by Chronic mTOR Suppression
por: Makarević, Jasmina, et al.
Publicado: (2018)

Resistance to the mTOR-inhibitor RAD001 elevates integrin α2- and β1-triggered motility, migration and invasion of prostate cancer cells
por: Tsaur, I, et al.
Publicado: (2012)

HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells
por: Juengel, Eva, et al.
Publicado: (2017)

Influence of the HDAC Inhibitor Valproic Acid on the Growth and Proliferation of Temsirolimus-Resistant Prostate Cancer Cells In Vitro
por: Makarević, Jasmina, et al.
Publicado: (2019)

Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib
por: Juengel, Eva, et al.
Publicado: (2015)

Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis
por: Wedel, Steffen, et al.
Publicado: (2011)

Amygdalin Blocks Bladder Cancer Cell Growth In Vitro by Diminishing Cyclin A and cdk2
por: Makarević, Jasmina, et al.
Publicado: (2014)

CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study
por: Tsaur, Igor, et al.
Publicado: (2015)

I Publish in I Edit? - Do Editorial Board Members of Urologic Journals Preferentially Publish Their Own Scientific Work?
por: Mani, Jens, et al.
Publicado: (2013)

HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A
por: Juengel, Eva, et al.
Publicado: (2014)

Publication of Original Research in Urologic Journals – A Neglected Orphan?
por: Mani, Jens, et al.
Publicado: (2012)

Amygdalin Influences Bladder Cancer Cell Adhesion and Invasion In Vitro
por: Makarević, Jasmina, et al.
Publicado: (2014)

sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients
por: Tsaur, Igor, et al.
Publicado: (2015)

Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells
por: Juengel, Eva, et al.
Publicado: (2009)

Chronic Sulforaphane Administration Inhibits Resistance to the mTOR-Inhibitor Everolimus in Bladder Cancer Cells
por: Justin, Saira, et al.
Publicado: (2020)

Olive Mill Wastewater Inhibits Growth and Proliferation of Cisplatin- and Gemcitabine-Resistant Bladder Cancer Cells In Vitro by Down-Regulating the Akt/mTOR-Signaling Pathway
por: Rutz, Jochen, et al.
Publicado: (2022)

Feasibility, complications and oncologic results of a limited inguinal lymph node dissection in the management of penile cancer
por: Tsaur, Igor, et al.
Publicado: (2015)

What should be the patient’s preference regarding the choice of hospital in the case of radical cystectomy? Evaluation of early complications after open radical cystectomy in a medium and high volume setting in one hospital
por: Mani, Jens, et al.
Publicado: (2016)

Increased tumor vascularization is associated with the amount of immune competent PD-1 positive cells in testicular germ cell tumors
por: Jennewein, Lukas, et al.
Publicado: (2018)

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
por: Park, Haeseong, et al.
Publicado: (2016)

Shikonin Inhibits Cell Growth of Sunitinib-Resistant Renal Cell Carcinoma by Activating the Necrosome Complex and Inhibiting the AKT/mTOR Signaling Pathway
por: Markowitsch, Sascha D., et al.
Publicado: (2022)

Evaluation of TKTL1 as a biomarker in serum of prostate cancer patients
por: Tsaur, Igor, et al.
Publicado: (2016)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
por: Hassan, Burhan, et al.
Publicado: (2014)

Mechanisms behind Temsirolimus Resistance Causing Reactivated Growth and Invasive Behavior of Bladder Cancer Cells In Vitro
por: Juengel, Eva, et al.
Publicado: (2019)

Concomitant Use of Sulforaphane Enhances Antitumor Efficacy of Sunitinib in Renal Cell Carcinoma In Vitro
por: Tsaur, Igor, et al.
Publicado: (2022)

New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma
por: Wedel, S A, et al.
Publicado: (2008)

Inhibitors of mTOR in aging and cancer
por: Zhavoronkov, Alexander
Publicado: (2015)

Gerosuppression by pan-mTOR inhibitors
por: Leontieva, Olga V., et al.
Publicado: (2016)

mTOR inhibitors in cancer therapy
por: Xie, Jianling, et al.
Publicado: (2016)

mTor Inhibitors for the Treatment of Endometriosis
por: Barra, Fabio, et al.
Publicado: (2018)

Targeting ganglioneuromas with mTOR inhibitors
por: Tao, Ting, et al.
Publicado: (2021)

Overview of Research into mTOR Inhibitors
por: Mao, Beibei, et al.
Publicado: (2022)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

Allyl-, Butyl- and Phenylethyl-Isothiocyanate Modulate Akt–mTOR and Cyclin–CDK Signaling in Gemcitabine- and Cisplatin-Resistant Bladder Cancer Cell Lines
por: Rutz, Jochen, et al.
Publicado: (2022)

Use of complementary and alternative medicine before and after organ removal due to urologic cancer
por: Mani, Jens, et al.
Publicado: (2015)

Assessment of PI3K/mTOR/AKT Pathway Elements to Serve as Biomarkers and Therapeutic Targets in Penile Cancer
por: Thomas, Anita, et al.
Publicado: (2021)

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2866pa99u7m69ud681ibuq2tnq